NASDAQ:ADXN Addex Therapeutics (ADXN) Stock Price, News & Analysis $7.94 +0.42 (+5.59%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Addex Therapeutics Stock (NASDAQ:ADXN) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Addex Therapeutics alerts:Sign Up Key Stats Today's Range$7.90▼$8.0150-Day Range$7.54▼$9.8952-Week Range$6.51▼$13.27Volume943 shsAverage Volume1,630 shsMarket Capitalization$8.42 millionP/E RatioN/ADividend YieldN/APrice Target$30.00Consensus RatingBuy Company Overview Addex Therapeutics Ltd discovers, develops, and commercializes small-molecule pharmaceutical products for central nervous system (CNS) disorders in Switzerland. The company focuses on the discovery of G-protein coupled receptors and enzymes. Its lead programs include Dipraglurant for the treatment of Parkinson's disease levodopa-induced dyskinesia and dystonia, and post-stroke/TBI recovery; ADX71149, a novel orally active metabotropic glutamate receptor subtype 2 positive allosteric modulator (mGlu2 PAM) for the treatment of epilepsy; and GABAB PAM for the treatment of pain, anxiety, overactive bladder, and addiction, as well as substance use disorder. Addex Therapeutics Ltd has license and collaboration agreement with Janssen Pharmaceuticals Inc. for the discovery, development, and commercialization of novel mGlu2 PAM compounds for the treatment of CNS and related diseases; license and research agreement with Indivior PLC discovery, development, and commercialization of novel GABAB PAM compounds for the treatment of addiction and other CNS diseases; and The CharcotMarieTooth Association to evaluate the role of GABAB PAM compounds in preclinical models of CMT1A. The company was formerly known as Addex Pharmaceuticals Ltd. Addex Therapeutics Ltd was founded in 2002 and is based in Geneva, Switzerland. Read More Addex Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks55th Percentile Overall ScoreADXN MarketRank™: Addex Therapeutics scored higher than 55% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingAddex Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageAddex Therapeutics has received no research coverage in the past 90 days.Read more about Addex Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Addex Therapeutics is -23.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Addex Therapeutics is -23.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAddex Therapeutics has a P/B Ratio of 0.77. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Addex Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted0.15% of the float of Addex Therapeutics has been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAddex Therapeutics does not currently pay a dividend.Dividend GrowthAddex Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted0.15% of the float of Addex Therapeutics has been sold short.Short Interest Ratio / Days to CoverAddex Therapeutics has a short interest ratio ("days to cover") of 0.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month News and Social Media3.3 / 5News SentimentN/A News SentimentAddex Therapeutics has a news sentiment score of 1.87. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.61 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Addex Therapeutics this week, compared to 0 articles on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Addex Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders15.00% of the stock of Addex Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 16.14% of the stock of Addex Therapeutics is held by institutions.Read more about Addex Therapeutics' insider trading history. Receive ADXN Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Addex Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address ADXN Stock News HeadlinesAddex Therapeutics Ltd (ADXN) - Yahoo FinanceJuly 17, 2025 | finance.yahoo.comADXN - Addex Therapeutics Ltd Price vs Fair Value - MorningstarJuly 2, 2025 | morningstar.comMMan Who Called Nvidia at $1.10 Says Buy This Now...In 2004, one man called Nvidia before just about anyone knew it existed. Now, this same guy says a new company could become the next to soar like Nvidia.August 15 at 2:00 AM | The Oxford Club (Ad)Stalicla secures CHF 2M investment led by Addex for neuropsychiatric drug developmentJune 30, 2025 | seekingalpha.comStalicla Secures CHF 2 Million Financing Led by Addex Therapeutics to Advance Precision Medicine Neurodevelopmental Disorder ProgramsJune 30, 2025 | globenewswire.comAddex Leads CHF 2 Million Investment in Stalicla to Advance Precision Medicine in Neuropsychiatric DisordersJune 30, 2025 | globenewswire.comAddex Shareholders Approve All Resolutions at Annual General MeetingJune 25, 2025 | globenewswire.comAddex Therapeutics Ltd (ADXN) Q1 2025 Earnings Call Highlights: Strategic Advances and ...June 20, 2025 | finance.yahoo.comSee More Headlines ADXN Stock Analysis - Frequently Asked Questions How have ADXN shares performed this year? Addex Therapeutics' stock was trading at $7.00 at the beginning of the year. Since then, ADXN shares have increased by 13.4% and is now trading at $7.94. How were Addex Therapeutics' earnings last quarter? Addex Therapeutics Ltd. Sponsored ADR (NASDAQ:ADXN) issued its earnings results on Friday, November, 22nd. The company reported ($2.77) EPS for the quarter, missing analysts' consensus estimates of ($1.40) by $1.37. Addex Therapeutics had a negative trailing twelve-month return on equity of 54.27% and a net margin of 3,584.49%. Read the conference call transcript. When did Addex Therapeutics' stock split? Addex Therapeutics shares reverse split on Monday, October 23rd 2023.The 1-20 reverse split was announced on Monday, October 23rd 2023. The number of shares owned by shareholders was adjusted after the closing bell on Monday, October 23rd 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. How do I buy shares of Addex Therapeutics? Shares of ADXN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Addex Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Addex Therapeutics investors own include Arista Networks (ANET), Adobe (ADBE), NVIDIA (NVDA), Broadcom (AVGO), GE Aerospace (GE), Vista Energy (VIST) and Arch Capital Group (ACGL). Company Calendar Last Earnings11/22/2024Today8/15/2025Next Earnings (Estimated)9/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADXN CIK1574232 Webwww.addextherapeutics.com Phone011-41-22-884-1555Fax41-22-884-1556Employees30Year FoundedN/APrice Target and Rating Average Price Target for Addex Therapeutics$30.00 High Price Target$30.00 Low Price Target$30.00 Potential Upside/Downside+277.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Trailing Twelve Months)($0.34) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$8.02 million Net Margins3,584.49% Pretax Margin-2,307.03% Return on Equity-54.27% Return on Assets-49.15% Debt Debt-to-Equity RatioN/A Current Ratio3.02 Quick Ratio3.02 Sales & Book Value Annual Sales$460 thousand Price / Sales18.30 Cash FlowN/A Price / Cash FlowN/A Book Value$10.37 per share Price / Book0.77Miscellaneous Outstanding Shares1,060,000Free Float901,000Market Cap$8.42 million OptionableNot Optionable Beta1.63 Social Links These 7 Stocks Will Be Magnificent in 2025Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.Get This Free Report This page (NASDAQ:ADXN) was last updated on 8/15/2025 by MarketBeat.com Staff From Our PartnersTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredAlex’s “Next Magnificent Seven” stocksThe original “Magnificent Seven” turned $7K into $1.18 million. Now, Alex Green has identified AI’s Next Ma...The Oxford Club | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredBONUS GUIDE - Ben Stein Prepares For the Next Financial CrisisWith inflation high, debt soaring, and global tensions rising, a financial storm may be brewing. Economist ...Goldco Precious Metals | SponsoredElon’s Secret Social Security BombshellTo All Americans Born Before April 16th, 1963: Did Trump Just Give The Green Light To Radically RE-DO Social S...Banyan Hill Publishing | SponsoredTrump set to Boost Social Security Checks by 400%?If you're collecting or planning to collect social security... You should see this presentation about Presi...InvestorPlace | SponsoredCrypto Income (almost instantly)How would you like to collect a small percentage of the $4 billion changing hands daily in the crypto market? ...Awesomely, LLC | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Addex Therapeutics Ltd. Sponsored ADR Please log in to your account or sign up in order to add this asset to your watchlist. Share Addex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.